Bluefish gets approval for six new pharmaceuticals
Bluefish Pharmaceuticals has expanded its product portfolio with six new approved pharmaceuticals in the past quarter. A number of European medical product authorities have granted approval for products pertaining to therapy for the central nervous system, cardiovascular disease, and stomach/bowel (proton pump inhibitors). The approved pharmaceutical substances are Gabapentin, Sertraline, Sumatriptan, Risperidon, Losartan and Lansoprazol. Sales for these pharmaceuticals total SEK 19.5 billion per year in the EU.“These new approvals attest to the quality of the company’s product portfolio,